Trading of Nifty 50 index futures on the Singapore stock exchange indicates that the Nifty could rise 88 points at the opening bell. Overseas, Asian stocks traded higher on Tuesday, after the tech-heavy Nasdaq Composite jumped to a record closing high following the U.S. Food and Drug Administration’s full approval of Pfizer and BioNTech’s Covid-19 vaccine.
The US Securities and Exchange Commission has reportedly began issuing new disclosure requirements to Chinese firms looking to list in New York, as part of a push to raise investor awareness of the risks involved.
Pfizer and BioNTech’s Covid-19 vaccine became the first in the US on Monday to be granted full approval by the Food and Drug Administration, clearing the path for more vaccine mandates.
US stocks finished higher Monday and the Nasdaq reached an all-time closing high, led by reopening stocks as the Food and Drug Administration approved its first Covid-19 vaccine. The FDA granted full approval for the two-dose Pfizer-BioNTech vaccine for Covid-19.
Domestic markets:
Back home, the domestic equity benchmarks managed to close with decent gains after a volatile session on Monday. The barometer index, the S&P BSE Sensex, advanced 226.47 points or 0.41% to 55,555.79. The Nifty 50 index gained 45.95 points or 0.28% to 16,496.45.
Foreign portfolio investors (FPIs) sold shares worth Rs 1,363.36 crore, while domestic institutional investors (DIIs), were net buyers to the tune of Rs 1,452.51 crore in the Indian equity market on 23 August, provisional data showed.
Published: August 24, 2021, 08:40 IST
Download Money9 App for the latest updates on Personal Finance.